Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8459302 | Radiotherapy and Oncology | 2018 | 8 Pages |
Abstract
The START trial results suggest that appropriately-dosed hypofractionated LNRT is safe in the long-term, according to patient and physician-assessed arm and shoulder symptoms. These findings are consistent with those reported after the same schedules delivered to the breast/chest wall.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Joanne S Haviland, Mariella Mannino, Clare Griffin, Nuria Porta, Mark Sydenham, Judith M. Bliss, John R. Yarnold, the START Trialists' Group the START Trialists' Group,